FOLLOW US

Biotechnology firm Verve Therapeutics is under fire as it confronts a proposed class action lawsuit claiming the company misled investors about the risks associated with its experimental gene-editing drug, Verve-101. The lawsuit, filed by Thomas Oldroyd in Massachusetts federal court on Tuesday, accuses the company of deceptive practices that contributed to a dramatic drop in its stock value.

Lawsuit Details and Allegations

Oldroyd’s suit seeks to represent investors who traded Verve securities from August 2022 through April 2024. The complaint alleges that Verve Therapeutics, based in Boston, failed to disclose crucial information about the Heart-1 clinical trial for Verve-101, which targets heterozygous familial hypercholesterolemia—a severe cardiovascular condition.

In August 2022, Verve reported to the U.S. Securities and Exchange Commission (SEC) about the initiation of the Heart-1 trial, noting potential risks related to serious adverse events and their impact on regulatory approval. However, Oldroyd contends that this disclosure was misleading because it did not reveal that even minor adverse events could lead to a halt in the trial's enrollment.

Verve Therapeutics Class Action Lawsuit : Subsequent Claims and Market Impact

The lawsuit further accuses Verve of making misleading statements in later financial reports. A November 2023 press release, for instance, suggested that the trial's safety profile was acceptable, despite acknowledging an adverse event that led to a heart attack in one patient. This press release allegedly downplayed the potential for halting the trial due to such events.

The true extent of the risks became apparent on April 2, 2024, when Verve announced the Heart-1 trial’s suspension due to issues with the drug’s delivery system. The revelation triggered a 34.9% plunge in Verve’s stock price, as detailed in the lawsuit.

Legal Actions and Representation

Oldroyd’s lawsuit accuses Verve Therapeutics and its executives of violating the Exchange Act and seeks compensation for the financial losses suffered by investors. The Rosen Law Firm PA's Joshua Baker represents Oldroyd, while Verve has yet to comment on the lawsuit or provide information about its legal counsel.

As the case unfolds, the biotech industry and investors alike will be watching closely to see how Verve Therapeutics navigates these serious allegations and the impact on its ongoing research and market performance.